Biopharma supply chains are becoming more complex and costly in the EU. This paper explores the causes and provides some “upstream” and “downstream” strategies that pharmaceutical and biotech companies can use to better manage complexity, cost, and risk.
This paper was developed by AIM, the supply chain leader for life science entrants and midsize biopharma companies. AIM is a Blue Matter company.
